Navigation Links
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Date:8/8/2013

WOODCLIFF LAKE, N.J., Aug. 8, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell lymphoma (CTCL).  E7777 is designed to have an improved purity profile and manufacturing process. It is currently in a pivotal trial intended to support its submission for approval.

The Orphan Drug Act (ODA) allows FDA to grant orphan status to a drug which has the potential for the treatment, diagnosis, or prevention of a rare disease/disorder that affects fewer than 200,000 people in the United States.

CTCL is a rare type of cancer that begins in the white blood cells and attacks the skin. It is one of several types of lymphoma collectively called non-Hodgkin lymphoma.

Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Media InquiriesInvestor InquiriesLaurie Landau

Alex Scott Eisai Inc.

Eisai Inc.201-746-2510

201-746-2177


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
2. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Agnitio Grants 10,000 New Licenses Globally this Financial Year
4. FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
5. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
6. Cardinal Health Foundation Invites Local Non-profit Organizations To Apply For Grants To Prevent Prescription Drug Abuse
7. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
8. FDA Grants Chimerix Fast Track Designation for CMX001 for the Prevention of Clinically Significant Cytomegalovirus Infection
9. Pancreatic Cancer Action Network Opposes Sequestration Cuts To National Institutes Of Health & Cancer Research Grants
10. State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
11. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... May 31, 2016   Plexus Technology Group, ... anesthesia information management systems (AIMS), is pleased to ... as Vice President of Technology. In this new ... aspects of the company,s technological development. He will ... to determine the expansion of new products, product ...
(Date:5/31/2016)... , May 31, 2016 ... market is progressing at a CAGR of 10.6% within ... was valued at US$0.46 bn in 2013. Owing to ... expected to reach US$0.88 bn by the end of ... derived from the market,s holistic representation in a research ...
(Date:5/31/2016)... , May 31, 2016 ... the initiation of a first-in-human clinical trial of its ... molecule - S101 is currently being developed for the ... study is designed to evaluate the safety and tolerability ... at several sites across the United States ...
Breaking Medicine Technology:
(Date:5/31/2016)... Atlanta, GA (PRWEB) , ... May 31, 2016 ... ... Contact Center Solutions , today announced it has been included by Gartner, ... 2016 report mentions a wide range of Contact Center Infrastructure technologies, some of ...
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader ... with e-Jan Networks Co., the leading provider of secure mobile remote access solution ... Networks’s leading CACHATTO remote access solution. Splashtop for CACHATTO will be ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph Medical Center (SJMC) ... exchange, which enables physicians at SJMC’s two hospital campuses, downtown and in the ... in the exchange. SJMC’s membership in the health information exchange underscores the hospital’s ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Twenty years ago ... experience, rather than trying to silence the voices they hear. But this approach has ... itself. , The method has steadily gained credibility and now is used around the ...
(Date:5/31/2016)... ... 31, 2016 , ... The University of Tennessee Medical Center ... the latest in Clinical Patient Pod (CPP) technologies provided through Jvion’s ... into the clinical workflow. These insights are empowering the more than 30 case ...
Breaking Medicine News(10 mins):